Alok Singh
Concepts (593)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 7 | 2024 | 259 | 2.190 |
Why?
| | Migraine Disorders | 3 | 2022 | 112 | 1.850 |
Why?
| | Mycobacterium tuberculosis | 10 | 2025 | 337 | 1.540 |
Why?
| | Leishmania donovani | 4 | 2016 | 12 | 1.440 |
Why?
| | Calcitonin Gene-Related Peptide | 2 | 2022 | 40 | 1.420 |
Why?
| | Tuberculosis | 7 | 2023 | 291 | 1.230 |
Why?
| | BCG Vaccine | 4 | 2022 | 27 | 1.220 |
Why?
| | Carboxylic Acids | 4 | 2013 | 34 | 1.140 |
Why?
| | Antitubercular Agents | 4 | 2025 | 216 | 1.080 |
Why?
| | Neurocysticercosis | 2 | 2018 | 8 | 1.070 |
Why?
| | Naturopathy | 1 | 2025 | 2 | 0.940 |
Why?
| | Macrophages | 9 | 2023 | 1511 | 0.920 |
Why?
| | Puerperal Disorders | 1 | 2026 | 37 | 0.920 |
Why?
| | Dinucleoside Phosphates | 2 | 2022 | 31 | 0.870 |
Why?
| | Gastric Outlet Obstruction | 1 | 2024 | 12 | 0.860 |
Why?
| | Self Expandable Metallic Stents | 1 | 2024 | 17 | 0.850 |
Why?
| | Mycobacterium bovis | 2 | 2021 | 15 | 0.850 |
Why?
| | Refuse Disposal | 1 | 2023 | 4 | 0.810 |
Why?
| | Waste Management | 1 | 2023 | 11 | 0.810 |
Why?
| | Gallstones | 1 | 2023 | 35 | 0.800 |
Why?
| | Antiemetics | 1 | 2024 | 49 | 0.800 |
Why?
| | Seizures | 2 | 2018 | 477 | 0.790 |
Why?
| | Viloxazine | 1 | 2022 | 1 | 0.770 |
Why?
| | Mite Infestations | 2 | 2020 | 9 | 0.760 |
Why?
| | Titanium | 3 | 2012 | 81 | 0.750 |
Why?
| | Oxygen | 3 | 2013 | 995 | 0.740 |
Why?
| | Methylphenidate | 1 | 2022 | 49 | 0.740 |
Why?
| | Piracetam | 1 | 2022 | 14 | 0.730 |
Why?
| | Virus Diseases | 2 | 2022 | 216 | 0.730 |
Why?
| | Dog Diseases | 2 | 2020 | 70 | 0.720 |
Why?
| | Tuberculosis Vaccines | 1 | 2021 | 5 | 0.710 |
Why?
| | Antihypertensive Agents | 1 | 2026 | 511 | 0.700 |
Why?
| | Nomograms | 1 | 2022 | 59 | 0.680 |
Why?
| | Myopia | 1 | 2022 | 59 | 0.680 |
Why?
| | Onium Compounds | 2 | 2017 | 8 | 0.670 |
Why?
| | Central Nervous System Stimulants | 1 | 2022 | 185 | 0.650 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2021 | 71 | 0.650 |
Why?
| | Cancer Vaccines | 1 | 2022 | 160 | 0.650 |
Why?
| | Ivermectin | 1 | 2020 | 14 | 0.650 |
Why?
| | Blood-Brain Barrier | 2 | 2021 | 155 | 0.640 |
Why?
| | Cytokines | 5 | 2022 | 2065 | 0.630 |
Why?
| | Blood Pressure | 3 | 2026 | 1769 | 0.630 |
Why?
| | Humans | 69 | 2026 | 144957 | 0.630 |
Why?
| | Tuberculosis, Multidrug-Resistant | 2 | 2017 | 50 | 0.630 |
Why?
| | Hypertension | 2 | 2026 | 1264 | 0.630 |
Why?
| | Deglutition | 1 | 2020 | 72 | 0.620 |
Why?
| | Hypogonadism | 1 | 2020 | 90 | 0.610 |
Why?
| | Mites | 1 | 2019 | 8 | 0.610 |
Why?
| | Cardiovascular Diseases | 7 | 2025 | 2171 | 0.600 |
Why?
| | Immunity, Cellular | 1 | 2021 | 272 | 0.600 |
Why?
| | Stents | 1 | 2023 | 556 | 0.590 |
Why?
| | Glucose Intolerance | 1 | 2020 | 142 | 0.580 |
Why?
| | Health Promotion | 1 | 2025 | 774 | 0.580 |
Why?
| | Nanostructures | 3 | 2024 | 117 | 0.570 |
Why?
| | Deglutition Disorders | 1 | 2020 | 147 | 0.560 |
Why?
| | Schiff Bases | 3 | 2012 | 7 | 0.550 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2022 | 428 | 0.550 |
Why?
| | Autophagy | 2 | 2020 | 286 | 0.540 |
Why?
| | Mannich Bases | 1 | 2017 | 1 | 0.540 |
Why?
| | Antineoplastic Agents | 4 | 2025 | 2197 | 0.530 |
Why?
| | Pyrazoles | 2 | 2021 | 510 | 0.530 |
Why?
| | Curcumin | 1 | 2017 | 25 | 0.520 |
Why?
| | Epilepsy | 1 | 2022 | 387 | 0.510 |
Why?
| | Glycolipids | 1 | 2017 | 52 | 0.510 |
Why?
| | Mycobacterium Infections, Nontuberculous | 2 | 2021 | 366 | 0.490 |
Why?
| | Image Enhancement | 1 | 2018 | 199 | 0.490 |
Why?
| | Leishmaniasis, Visceral | 1 | 2016 | 24 | 0.480 |
Why?
| | Spectrophotometry, Infrared | 7 | 2013 | 55 | 0.480 |
Why?
| | Pregnancy Complications | 1 | 2022 | 592 | 0.480 |
Why?
| | Anti-Bacterial Agents | 5 | 2019 | 1915 | 0.480 |
Why?
| | Enterobacter cloacae | 2 | 2026 | 5 | 0.480 |
Why?
| | X-Ray Diffraction | 7 | 2013 | 104 | 0.470 |
Why?
| | Positron-Emission Tomography | 4 | 2025 | 343 | 0.470 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2016 | 81 | 0.470 |
Why?
| | Animals | 35 | 2025 | 38109 | 0.470 |
Why?
| | India | 5 | 2025 | 218 | 0.470 |
Why?
| | Multiple Sclerosis | 1 | 2021 | 484 | 0.460 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2017 | 208 | 0.460 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.440 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.440 |
Why?
| | Contrast Media | 1 | 2018 | 488 | 0.430 |
Why?
| | Eflornithine | 1 | 2014 | 8 | 0.420 |
Why?
| | Drug Resistance | 2 | 2014 | 153 | 0.410 |
Why?
| | Host-Pathogen Interactions | 2 | 2017 | 371 | 0.410 |
Why?
| | Gene Expression Profiling | 3 | 2016 | 1786 | 0.410 |
Why?
| | T-Lymphocytes | 2 | 2021 | 1982 | 0.400 |
Why?
| | Iron Compounds | 1 | 2013 | 7 | 0.390 |
Why?
| | Metabolic Diseases | 2 | 2025 | 114 | 0.390 |
Why?
| | Metals | 2 | 2014 | 142 | 0.390 |
Why?
| | Brain | 4 | 2018 | 2941 | 0.390 |
Why?
| | Insulin Resistance | 2 | 2024 | 1241 | 0.380 |
Why?
| | Lipid Metabolism | 1 | 2016 | 528 | 0.380 |
Why?
| | Double-Blind Method | 3 | 2022 | 2029 | 0.380 |
Why?
| | Organometallic Compounds | 2 | 2014 | 112 | 0.380 |
Why?
| | Proteome | 2 | 2015 | 518 | 0.370 |
Why?
| | Coordination Complexes | 1 | 2012 | 13 | 0.370 |
Why?
| | Oxides | 1 | 2012 | 51 | 0.360 |
Why?
| | Staphylococcus aureus | 4 | 2019 | 460 | 0.360 |
Why?
| | Apoptosis | 5 | 2025 | 2430 | 0.360 |
Why?
| | Urothelium | 2 | 2022 | 33 | 0.350 |
Why?
| | DNA, Mitochondrial | 1 | 2013 | 212 | 0.350 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 2 | 2024 | 219 | 0.350 |
Why?
| | Tuberculosis, Pulmonary | 2 | 2025 | 131 | 0.350 |
Why?
| | Genes, BRCA1 | 1 | 2011 | 45 | 0.350 |
Why?
| | Reactive Oxygen Species | 2 | 2019 | 621 | 0.350 |
Why?
| | Particle Size | 2 | 2010 | 411 | 0.340 |
Why?
| | MicroRNAs | 2 | 2024 | 701 | 0.340 |
Why?
| | Aziridines | 1 | 2011 | 6 | 0.340 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2026 | 2584 | 0.340 |
Why?
| | Aza Compounds | 1 | 2011 | 13 | 0.340 |
Why?
| | Epigenomics | 1 | 2011 | 114 | 0.330 |
Why?
| | Iron | 2 | 2016 | 359 | 0.330 |
Why?
| | Carbohydrates | 1 | 2011 | 66 | 0.330 |
Why?
| | Gene Silencing | 1 | 2011 | 205 | 0.330 |
Why?
| | Membrane Proteins | 3 | 2022 | 1167 | 0.320 |
Why?
| | HIV Infections | 3 | 2022 | 3154 | 0.320 |
Why?
| | Headache | 2 | 2022 | 150 | 0.320 |
Why?
| | Proteomics | 2 | 2015 | 1195 | 0.320 |
Why?
| | Monocytes | 2 | 2016 | 538 | 0.320 |
Why?
| | Enzyme Inhibitors | 4 | 2019 | 826 | 0.320 |
Why?
| | Magnetic Resonance Imaging | 5 | 2018 | 3869 | 0.310 |
Why?
| | Disease Models, Animal | 11 | 2025 | 4569 | 0.310 |
Why?
| | Thorium | 1 | 2009 | 2 | 0.310 |
Why?
| | Breast Neoplasms | 3 | 2011 | 2456 | 0.310 |
Why?
| | Fluorescent Dyes | 2 | 2025 | 330 | 0.300 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2010 | 124 | 0.290 |
Why?
| | Female | 25 | 2026 | 78376 | 0.290 |
Why?
| | Mice | 16 | 2025 | 18365 | 0.290 |
Why?
| | Adult | 13 | 2026 | 40506 | 0.280 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2026 | 3890 | 0.280 |
Why?
| | Treatment Outcome | 7 | 2026 | 11695 | 0.270 |
Why?
| | Population Surveillance | 1 | 2011 | 485 | 0.270 |
Why?
| | Death, Sudden, Cardiac | 1 | 2010 | 230 | 0.270 |
Why?
| | Models, Chemical | 1 | 2009 | 269 | 0.270 |
Why?
| | Microbial Viability | 2 | 2019 | 90 | 0.270 |
Why?
| | Immunity, Innate | 3 | 2023 | 846 | 0.260 |
Why?
| | Bacterial Load | 2 | 2017 | 67 | 0.260 |
Why?
| | Sports | 1 | 2010 | 211 | 0.260 |
Why?
| | Young Adult | 5 | 2024 | 14126 | 0.250 |
Why?
| | Plant Diseases | 2 | 2024 | 44 | 0.250 |
Why?
| | Microbial Sensitivity Tests | 3 | 2017 | 371 | 0.250 |
Why?
| | Prospective Studies | 5 | 2026 | 7997 | 0.250 |
Why?
| | Insulin, Short-Acting | 1 | 2026 | 8 | 0.240 |
Why?
| | Pyrroles | 2 | 2022 | 218 | 0.240 |
Why?
| | Neoplasms | 3 | 2023 | 2884 | 0.240 |
Why?
| | Gastrointestinal Microbiome | 2 | 2025 | 771 | 0.240 |
Why?
| | Organoids | 2 | 2018 | 141 | 0.240 |
Why?
| | Vitamin B 12 Deficiency | 1 | 2026 | 77 | 0.240 |
Why?
| | Dysbiosis | 2 | 2025 | 187 | 0.230 |
Why?
| | Pyridines | 3 | 2022 | 605 | 0.230 |
Why?
| | Phage Therapy | 1 | 2025 | 17 | 0.230 |
Why?
| | Jaundice, Obstructive | 1 | 2025 | 3 | 0.230 |
Why?
| | Vitamin B 12 | 1 | 2026 | 127 | 0.230 |
Why?
| | Lipid Droplets | 1 | 2025 | 21 | 0.230 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2026 | 109 | 0.230 |
Why?
| | Enterobacteriaceae Infections | 1 | 2025 | 41 | 0.220 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2025 | 22 | 0.220 |
Why?
| | Urbanization | 1 | 2025 | 28 | 0.220 |
Why?
| | Calcium Channel Blockers | 1 | 2026 | 165 | 0.220 |
Why?
| | Dogs | 3 | 2024 | 438 | 0.220 |
Why?
| | Trichoderma | 1 | 2024 | 28 | 0.220 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1721 | 0.220 |
Why?
| | Water | 2 | 2025 | 469 | 0.220 |
Why?
| | Middle Aged | 11 | 2026 | 35928 | 0.220 |
Why?
| | Aniline Compounds | 1 | 2025 | 119 | 0.210 |
Why?
| | Recurrence | 2 | 2018 | 1135 | 0.210 |
Why?
| | Moringa oleifera | 1 | 2023 | 3 | 0.210 |
Why?
| | Extreme Heat | 1 | 2024 | 8 | 0.210 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2024 | 20 | 0.210 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3550 | 0.210 |
Why?
| | Environmental Monitoring | 2 | 2023 | 378 | 0.200 |
Why?
| | Solid Waste | 1 | 2023 | 3 | 0.200 |
Why?
| | Imidazoles | 1 | 2025 | 254 | 0.200 |
Why?
| | Glutamine | 1 | 2024 | 109 | 0.200 |
Why?
| | Bacteriophages | 1 | 2025 | 111 | 0.200 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2025 | 241 | 0.200 |
Why?
| | Nausea | 1 | 2024 | 111 | 0.200 |
Why?
| | Biofilms | 1 | 2026 | 278 | 0.200 |
Why?
| | Cholecystectomy | 1 | 2023 | 59 | 0.200 |
Why?
| | Drug Repositioning | 3 | 2019 | 41 | 0.200 |
Why?
| | Cold Temperature | 1 | 2025 | 209 | 0.200 |
Why?
| | Cognition Disorders | 2 | 2018 | 538 | 0.200 |
Why?
| | Pancreatitis | 1 | 2024 | 145 | 0.200 |
Why?
| | Vomiting | 1 | 2024 | 130 | 0.190 |
Why?
| | Risk Reduction Behavior | 1 | 2025 | 226 | 0.190 |
Why?
| | Spectroscopy, Mossbauer | 2 | 2013 | 2 | 0.190 |
Why?
| | Urinary Tract Infections | 1 | 2025 | 203 | 0.190 |
Why?
| | Cities | 1 | 2023 | 143 | 0.190 |
Why?
| | Nanoparticles | 1 | 2009 | 520 | 0.190 |
Why?
| | Magnetic Resonance Spectroscopy | 5 | 2012 | 631 | 0.190 |
Why?
| | Powders | 3 | 2012 | 44 | 0.190 |
Why?
| | Postpartum Period | 1 | 2026 | 365 | 0.190 |
Why?
| | Capsules | 1 | 2022 | 43 | 0.190 |
Why?
| | Life Style | 1 | 2025 | 479 | 0.190 |
Why?
| | Aging | 2 | 2018 | 1966 | 0.190 |
Why?
| | Heat Stress Disorders | 1 | 2024 | 84 | 0.190 |
Why?
| | Ligands | 4 | 2012 | 674 | 0.190 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2026 | 269 | 0.190 |
Why?
| | Pancreas | 2 | 2024 | 342 | 0.190 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 735 | 0.180 |
Why?
| | Chromatography, Liquid | 2 | 2015 | 454 | 0.180 |
Why?
| | Insulin | 2 | 2026 | 2507 | 0.180 |
Why?
| | Electrons | 3 | 2012 | 88 | 0.180 |
Why?
| | Kinetics | 4 | 2023 | 1629 | 0.180 |
Why?
| | Cardiovascular System | 1 | 2024 | 138 | 0.180 |
Why?
| | Climate Change | 1 | 2025 | 199 | 0.180 |
Why?
| | Pathogen-Associated Molecular Pattern Molecules | 1 | 2022 | 7 | 0.180 |
Why?
| | Soil Microbiology | 1 | 2024 | 218 | 0.180 |
Why?
| | Spiro Compounds | 1 | 2022 | 17 | 0.180 |
Why?
| | Adolescent | 7 | 2025 | 22453 | 0.180 |
Why?
| | Delayed-Action Preparations | 1 | 2022 | 183 | 0.180 |
Why?
| | Vero Cells | 2 | 2021 | 84 | 0.180 |
Why?
| | Pacinian Corpuscles | 1 | 2021 | 1 | 0.170 |
Why?
| | Ketones | 2 | 2012 | 53 | 0.170 |
Why?
| | Dexamethasone | 1 | 2024 | 372 | 0.170 |
Why?
| | Caenorhabditis elegans Proteins | 1 | 2024 | 210 | 0.170 |
Why?
| | Glucose | 2 | 2026 | 1049 | 0.170 |
Why?
| | Male | 13 | 2026 | 72406 | 0.170 |
Why?
| | Nerve Fibers | 1 | 2022 | 104 | 0.170 |
Why?
| | Mass Spectrometry | 3 | 2014 | 750 | 0.170 |
Why?
| | Optical Imaging | 2 | 2025 | 64 | 0.170 |
Why?
| | Acetamides | 1 | 2021 | 38 | 0.170 |
Why?
| | Receptor, trkB | 1 | 2021 | 36 | 0.170 |
Why?
| | Deficiency Diseases | 1 | 2020 | 10 | 0.170 |
Why?
| | Iodine Radioisotopes | 1 | 2021 | 137 | 0.170 |
Why?
| | Pregnancy | 2 | 2026 | 7191 | 0.170 |
Why?
| | Sulfonamides | 1 | 2025 | 581 | 0.170 |
Why?
| | Mice, Inbred BALB C | 3 | 2019 | 1253 | 0.160 |
Why?
| | Diverticulum, Esophageal | 1 | 2020 | 4 | 0.160 |
Why?
| | Myeloid Cells | 1 | 2022 | 148 | 0.160 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2026 | 642 | 0.160 |
Why?
| | Permeability | 1 | 2021 | 168 | 0.160 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 121 | 0.160 |
Why?
| | Rural Population | 1 | 2025 | 650 | 0.160 |
Why?
| | Staphylococcal Infections | 4 | 2019 | 390 | 0.160 |
Why?
| | Water Pollutants, Chemical | 1 | 2023 | 234 | 0.160 |
Why?
| | History, 21st Century | 1 | 2021 | 219 | 0.160 |
Why?
| | Esophageal Motility Disorders | 1 | 2020 | 29 | 0.160 |
Why?
| | Piperidines | 1 | 2022 | 217 | 0.160 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 405 | 0.160 |
Why?
| | Pyrimidines | 2 | 2021 | 533 | 0.160 |
Why?
| | Radiation Dosage | 1 | 2021 | 193 | 0.160 |
Why?
| | CD4 Antigens | 2 | 2017 | 139 | 0.160 |
Why?
| | Cell Line | 2 | 2016 | 2882 | 0.150 |
Why?
| | Blood Glucose | 3 | 2026 | 2330 | 0.150 |
Why?
| | Drug Synergism | 2 | 2017 | 357 | 0.150 |
Why?
| | History, 20th Century | 1 | 2021 | 325 | 0.150 |
Why?
| | Drug Discovery | 2 | 2018 | 155 | 0.150 |
Why?
| | Analgesics | 1 | 2022 | 231 | 0.150 |
Why?
| | Rats | 4 | 2022 | 5614 | 0.150 |
Why?
| | Caspases | 1 | 2020 | 232 | 0.150 |
Why?
| | Tomography, Optical Coherence | 1 | 2022 | 271 | 0.150 |
Why?
| | Anticonvulsants | 1 | 2022 | 242 | 0.150 |
Why?
| | Diarylquinolines | 1 | 2019 | 16 | 0.150 |
Why?
| | Whole Body Imaging | 1 | 2019 | 29 | 0.150 |
Why?
| | Antibodies, Neutralizing | 1 | 2022 | 341 | 0.150 |
Why?
| | Molecular Structure | 3 | 2025 | 501 | 0.150 |
Why?
| | Granulosa Cells | 1 | 2019 | 33 | 0.150 |
Why?
| | Genome, Bacterial | 1 | 2020 | 156 | 0.150 |
Why?
| | Pyruvates | 1 | 2019 | 24 | 0.150 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 2 | 2023 | 88 | 0.150 |
Why?
| | Glucose Tolerance Test | 1 | 2020 | 361 | 0.150 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 194 | 0.140 |
Why?
| | Biomarkers, Tumor | 1 | 2026 | 1322 | 0.140 |
Why?
| | Vitamin D Deficiency | 1 | 2020 | 186 | 0.140 |
Why?
| | Fasting | 1 | 2020 | 277 | 0.140 |
Why?
| | Adenocarcinoma | 1 | 2026 | 931 | 0.140 |
Why?
| | Case-Control Studies | 3 | 2026 | 3608 | 0.140 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2019 | 187 | 0.140 |
Why?
| | Oocytes | 1 | 2019 | 178 | 0.140 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2026 | 2147 | 0.140 |
Why?
| | Child | 6 | 2024 | 22657 | 0.140 |
Why?
| | Thienamycins | 1 | 2017 | 3 | 0.140 |
Why?
| | Botrytis | 1 | 2017 | 2 | 0.140 |
Why?
| | Gene Expression | 2 | 2020 | 1490 | 0.140 |
Why?
| | Hypoglycemic Agents | 2 | 2026 | 1389 | 0.130 |
Why?
| | Cicer | 1 | 2017 | 3 | 0.130 |
Why?
| | Mycobacterium marinum | 1 | 2017 | 4 | 0.130 |
Why?
| | Mycobacterium leprae | 1 | 2017 | 10 | 0.130 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 477 | 0.130 |
Why?
| | Gene Expression Regulation | 2 | 2018 | 2609 | 0.130 |
Why?
| | Basidiomycota | 1 | 2017 | 27 | 0.130 |
Why?
| | Ethambutol | 1 | 2017 | 27 | 0.130 |
Why?
| | Amikacin | 1 | 2017 | 29 | 0.130 |
Why?
| | Immunization | 1 | 2019 | 374 | 0.130 |
Why?
| | Leprosy | 1 | 2017 | 25 | 0.130 |
Why?
| | Thymocytes | 1 | 2017 | 34 | 0.130 |
Why?
| | Ruthenium | 2 | 2014 | 34 | 0.130 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2017 | 68 | 0.130 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2018 | 132 | 0.130 |
Why?
| | Brain Edema | 1 | 2017 | 62 | 0.130 |
Why?
| | Brain Mapping | 2 | 2018 | 537 | 0.130 |
Why?
| | HIV | 1 | 2018 | 250 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
| | Obesity | 1 | 2011 | 3082 | 0.130 |
Why?
| | Genetic Predisposition to Disease | 1 | 2026 | 2365 | 0.130 |
Why?
| | Aged | 5 | 2026 | 25947 | 0.130 |
Why?
| | Disease | 1 | 2018 | 98 | 0.130 |
Why?
| | Demyelinating Diseases | 1 | 2017 | 84 | 0.130 |
Why?
| | Immune Evasion | 1 | 2017 | 64 | 0.130 |
Why?
| | Forkhead Transcription Factors | 1 | 2018 | 202 | 0.130 |
Why?
| | Prostatic Neoplasms | 1 | 2024 | 978 | 0.130 |
Why?
| | Neutropenia | 1 | 2017 | 155 | 0.120 |
Why?
| | Immunotherapy | 1 | 2021 | 657 | 0.120 |
Why?
| | Learning | 1 | 2021 | 452 | 0.120 |
Why?
| | Beclin-1 | 1 | 2016 | 11 | 0.120 |
Why?
| | Amino Acids | 1 | 2020 | 522 | 0.120 |
Why?
| | Arsenic | 1 | 2017 | 66 | 0.120 |
Why?
| | Ubiquitin-Conjugating Enzymes | 1 | 2016 | 17 | 0.120 |
Why?
| | Chloride Channel Agonists | 1 | 2017 | 109 | 0.120 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 111 | 0.120 |
Why?
| | Autophagy-Related Proteins | 1 | 2016 | 46 | 0.120 |
Why?
| | Influenza, Human | 1 | 2022 | 617 | 0.120 |
Why?
| | Drug Combinations | 1 | 2017 | 392 | 0.120 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2017 | 95 | 0.120 |
Why?
| | Ions | 1 | 2016 | 71 | 0.120 |
Why?
| | Tandem Mass Spectrometry | 2 | 2020 | 577 | 0.120 |
Why?
| | Signal Transduction | 4 | 2021 | 5233 | 0.120 |
Why?
| | Parasites | 1 | 2016 | 44 | 0.120 |
Why?
| | Up-Regulation | 2 | 2016 | 852 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2022 | 917 | 0.110 |
Why?
| | Oxidative Stress | 3 | 2019 | 1339 | 0.110 |
Why?
| | Urinary Bladder | 1 | 2017 | 194 | 0.110 |
Why?
| | Oryza | 2 | 2014 | 32 | 0.110 |
Why?
| | T-Lymphocyte Subsets | 1 | 2017 | 415 | 0.110 |
Why?
| | Neuroimaging | 1 | 2017 | 292 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 966 | 0.110 |
Why?
| | Glycoside Hydrolase Inhibitors | 1 | 2014 | 1 | 0.110 |
Why?
| | alpha-Glucosidases | 1 | 2014 | 9 | 0.110 |
Why?
| | Spectrometry, Fluorescence | 2 | 2014 | 168 | 0.110 |
Why?
| | Quinolones | 1 | 2017 | 201 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2016 | 521 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2021 | 1141 | 0.110 |
Why?
| | Aminophenols | 1 | 2017 | 201 | 0.110 |
Why?
| | Logistic Models | 2 | 2017 | 2119 | 0.110 |
Why?
| | Palladium | 1 | 2014 | 18 | 0.110 |
Why?
| | Immunoblotting | 1 | 2015 | 300 | 0.110 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2017 | 389 | 0.110 |
Why?
| | Administration, Intranasal | 2 | 2026 | 93 | 0.110 |
Why?
| | Ornithine Decarboxylase | 1 | 2014 | 13 | 0.110 |
Why?
| | Subcellular Fractions | 1 | 2014 | 74 | 0.100 |
Why?
| | Electroencephalography | 1 | 2017 | 551 | 0.100 |
Why?
| | Spermidine | 1 | 2014 | 17 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 341 | 0.100 |
Why?
| | Polyamines | 1 | 2014 | 42 | 0.100 |
Why?
| | Prognosis | 2 | 2026 | 4293 | 0.100 |
Why?
| | Antioxidants | 1 | 2017 | 549 | 0.100 |
Why?
| | Free Radicals | 1 | 2014 | 110 | 0.100 |
Why?
| | GTP Phosphohydrolases | 1 | 2014 | 93 | 0.100 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2011 | 157 | 0.100 |
Why?
| | Agriculture | 2 | 2024 | 104 | 0.100 |
Why?
| | Powder Diffraction | 1 | 2013 | 3 | 0.100 |
Why?
| | Body Mass Index | 2 | 2013 | 2438 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2026 | 5417 | 0.100 |
Why?
| | Vaccination | 1 | 2022 | 1423 | 0.100 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 927 | 0.090 |
Why?
| | Postprandial Period | 1 | 2013 | 118 | 0.090 |
Why?
| | Magnetic Phenomena | 1 | 2012 | 12 | 0.090 |
Why?
| | Administration, Intravenous | 2 | 2026 | 170 | 0.090 |
Why?
| | Protein Folding | 1 | 2014 | 279 | 0.090 |
Why?
| | Vanadates | 1 | 2012 | 17 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2118 | 0.090 |
Why?
| | Molecular Weight | 1 | 2012 | 327 | 0.090 |
Why?
| | Glutathione | 1 | 2014 | 375 | 0.090 |
Why?
| | Age Factors | 1 | 2019 | 3335 | 0.090 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2011 | 26 | 0.090 |
Why?
| | Mice, Inbred C57BL | 4 | 2025 | 5997 | 0.090 |
Why?
| | Genome, Plant | 1 | 2011 | 34 | 0.090 |
Why?
| | Droughts | 1 | 2011 | 32 | 0.090 |
Why?
| | Antimony | 1 | 2011 | 4 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1695 | 0.090 |
Why?
| | Mental Disorders | 1 | 2020 | 1172 | 0.090 |
Why?
| | Lung | 5 | 2025 | 4109 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2017 | 883 | 0.080 |
Why?
| | Amides | 1 | 2011 | 101 | 0.080 |
Why?
| | Gallbladder Neoplasms | 1 | 2011 | 20 | 0.080 |
Why?
| | Pentanones | 1 | 2010 | 3 | 0.080 |
Why?
| | Stereoisomerism | 1 | 2011 | 105 | 0.080 |
Why?
| | Protozoan Proteins | 1 | 2011 | 93 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2024 | 1462 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2024 | 2642 | 0.080 |
Why?
| | DNA Repair | 2 | 2011 | 256 | 0.080 |
Why?
| | Alloys | 1 | 2010 | 38 | 0.080 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5872 | 0.080 |
Why?
| | Cognition | 1 | 2018 | 1269 | 0.080 |
Why?
| | Streptococcus pneumoniae | 1 | 2011 | 177 | 0.080 |
Why?
| | Tuberculosis, Spinal | 1 | 2009 | 8 | 0.080 |
Why?
| | Polymers | 1 | 2014 | 499 | 0.080 |
Why?
| | Epidural Abscess | 1 | 2009 | 7 | 0.080 |
Why?
| | HeLa Cells | 2 | 2025 | 650 | 0.080 |
Why?
| | Magnetics | 1 | 2009 | 48 | 0.080 |
Why?
| | Proto-Oncogenes | 1 | 2009 | 29 | 0.070 |
Why?
| | Quantitative Trait Loci | 1 | 2011 | 374 | 0.070 |
Why?
| | Acetates | 1 | 2009 | 80 | 0.070 |
Why?
| | Temperature | 1 | 2012 | 679 | 0.070 |
Why?
| | DNA Methylation | 2 | 2011 | 683 | 0.070 |
Why?
| | Genes, Tumor Suppressor | 1 | 2009 | 83 | 0.070 |
Why?
| | Culture Media | 2 | 2026 | 161 | 0.070 |
Why?
| | Biomarkers | 3 | 2017 | 4275 | 0.070 |
Why?
| | Peptides | 1 | 2014 | 998 | 0.070 |
Why?
| | Cause of Death | 1 | 2010 | 472 | 0.070 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 598 | 0.060 |
Why?
| | Protein Binding | 3 | 2024 | 2276 | 0.060 |
Why?
| | Copper | 1 | 2008 | 113 | 0.060 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1258 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2011 | 531 | 0.060 |
Why?
| | Reticulocyte Count | 1 | 2026 | 7 | 0.060 |
Why?
| | Erythrocyte Indices | 1 | 2026 | 33 | 0.060 |
Why?
| | Adsorption | 2 | 2023 | 157 | 0.060 |
Why?
| | Time Factors | 1 | 2017 | 7183 | 0.060 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2026 | 115 | 0.060 |
Why?
| | Administration, Mucosal | 1 | 2025 | 2 | 0.060 |
Why?
| | Injections, Intramuscular | 1 | 2026 | 141 | 0.060 |
Why?
| | Bacterial Adhesion | 1 | 2026 | 110 | 0.060 |
Why?
| | Histocytochemistry | 1 | 2025 | 79 | 0.060 |
Why?
| | RNA | 2 | 2023 | 940 | 0.060 |
Why?
| | Biological Control Agents | 1 | 2024 | 3 | 0.060 |
Why?
| | Pest Control, Biological | 1 | 2024 | 9 | 0.060 |
Why?
| | Salmonella typhi | 1 | 2005 | 12 | 0.060 |
Why?
| | Healthy Lifestyle | 1 | 2025 | 37 | 0.060 |
Why?
| | Typhoid Fever | 1 | 2005 | 12 | 0.060 |
Why?
| | Species Specificity | 1 | 2026 | 574 | 0.050 |
Why?
| | Mutation | 2 | 2013 | 4099 | 0.050 |
Why?
| | Zinc | 1 | 2008 | 295 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2026 | 575 | 0.050 |
Why?
| | Rosaniline Dyes | 1 | 2023 | 15 | 0.050 |
Why?
| | Sulfuric Acids | 1 | 2023 | 12 | 0.050 |
Why?
| | Interleukin-1 | 1 | 2008 | 961 | 0.050 |
Why?
| | Hemoglobins | 1 | 2026 | 384 | 0.050 |
Why?
| | Interferon-Induced Helicase, IFIH1 | 1 | 2023 | 19 | 0.050 |
Why?
| | Microscopy | 1 | 2025 | 156 | 0.050 |
Why?
| | Nucleotidyltransferases | 1 | 2023 | 31 | 0.050 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2023 | 53 | 0.050 |
Why?
| | Prevalence | 1 | 2011 | 2836 | 0.050 |
Why?
| | Molecular Docking Simulation | 1 | 2024 | 124 | 0.050 |
Why?
| | Chickens | 1 | 2024 | 191 | 0.050 |
Why?
| | Risk Factors | 2 | 2024 | 10792 | 0.050 |
Why?
| | Inhibitory Concentration 50 | 2 | 2014 | 91 | 0.050 |
Why?
| | Microchemistry | 1 | 2003 | 19 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 489 | 0.050 |
Why?
| | Administration, Oral | 1 | 2025 | 848 | 0.050 |
Why?
| | Nitric Oxide | 1 | 2008 | 897 | 0.050 |
Why?
| | Neuropsychological Tests | 2 | 2018 | 1137 | 0.050 |
Why?
| | Soil | 1 | 2024 | 214 | 0.050 |
Why?
| | Models, Biological | 1 | 2010 | 1822 | 0.050 |
Why?
| | Methotrexate | 1 | 2024 | 240 | 0.050 |
Why?
| | Animals, Wild | 1 | 2022 | 61 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2925 | 0.050 |
Why?
| | Plants | 1 | 2024 | 226 | 0.050 |
Why?
| | Metagenomics | 1 | 2024 | 181 | 0.050 |
Why?
| | Neutralization Tests | 1 | 2022 | 76 | 0.050 |
Why?
| | Lymph Nodes | 1 | 2025 | 502 | 0.050 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2023 | 561 | 0.050 |
Why?
| | Models, Animal | 1 | 2024 | 392 | 0.050 |
Why?
| | Administration, Intravesical | 1 | 2021 | 17 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2020 | 4155 | 0.040 |
Why?
| | Mammals | 1 | 2023 | 293 | 0.040 |
Why?
| | Molecular Dynamics Simulation | 1 | 2024 | 260 | 0.040 |
Why?
| | Viral Envelope Proteins | 1 | 2022 | 98 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2005 | 1054 | 0.040 |
Why?
| | Thermodynamics | 1 | 2023 | 426 | 0.040 |
Why?
| | Crystallography, X-Ray | 2 | 2014 | 493 | 0.040 |
Why?
| | Reward | 1 | 2024 | 247 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2024 | 320 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2022 | 130 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2025 | 780 | 0.040 |
Why?
| | Cricetinae | 1 | 2021 | 304 | 0.040 |
Why?
| | Hypoglycemia | 1 | 2026 | 477 | 0.040 |
Why?
| | Biosensing Techniques | 1 | 2003 | 139 | 0.040 |
Why?
| | Survival Rate | 1 | 2026 | 2092 | 0.040 |
Why?
| | Genotype | 1 | 2026 | 1835 | 0.040 |
Why?
| | Hot Temperature | 1 | 2024 | 407 | 0.040 |
Why?
| | CRISPR-Cas Systems | 1 | 2022 | 170 | 0.040 |
Why?
| | Feces | 1 | 2024 | 513 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 434 | 0.040 |
Why?
| | Base Composition | 1 | 2020 | 82 | 0.040 |
Why?
| | Medical Illustration | 1 | 2020 | 10 | 0.040 |
Why?
| | Azides | 1 | 2020 | 47 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 154 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2021 | 117 | 0.040 |
Why?
| | Skin Diseases, Parasitic | 1 | 2020 | 3 | 0.040 |
Why?
| | Caenorhabditis elegans | 1 | 2024 | 337 | 0.040 |
Why?
| | Ubiquitination | 1 | 2020 | 118 | 0.040 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2021 | 148 | 0.040 |
Why?
| | Guinea Pigs | 1 | 2020 | 159 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2022 | 496 | 0.040 |
Why?
| | Autoradiography | 1 | 2019 | 65 | 0.040 |
Why?
| | Plasticizers | 1 | 2019 | 20 | 0.040 |
Why?
| | Diethylhexyl Phthalate | 1 | 2019 | 15 | 0.040 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2019 | 16 | 0.040 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2019 | 75 | 0.040 |
Why?
| | Transferrin | 1 | 2019 | 50 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2020 | 342 | 0.040 |
Why?
| | Computational Biology | 1 | 2024 | 681 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2021 | 509 | 0.040 |
Why?
| | Public Health | 1 | 2024 | 566 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1890 | 0.030 |
Why?
| | Esophagus | 1 | 2020 | 261 | 0.030 |
Why?
| | Phenotype | 2 | 2020 | 3164 | 0.030 |
Why?
| | Methylnitrosourea | 1 | 2017 | 7 | 0.030 |
Why?
| | Cell Physiological Phenomena | 1 | 2018 | 19 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2022 | 672 | 0.030 |
Why?
| | Plant Shoots | 1 | 2017 | 3 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2022 | 893 | 0.030 |
Why?
| | Antibiosis | 1 | 2017 | 10 | 0.030 |
Why?
| | Neuregulin-1 | 1 | 2018 | 49 | 0.030 |
Why?
| | Models, Molecular | 2 | 2014 | 1619 | 0.030 |
Why?
| | Core Binding Factor Alpha 3 Subunit | 1 | 2017 | 6 | 0.030 |
Why?
| | Disease Resistance | 1 | 2017 | 29 | 0.030 |
Why?
| | NADH, NADPH Oxidoreductases | 1 | 2017 | 24 | 0.030 |
Why?
| | Catalase | 1 | 2017 | 130 | 0.030 |
Why?
| | Depressive Disorder | 1 | 2020 | 387 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2020 | 824 | 0.030 |
Why?
| | Anxiety Disorders | 1 | 2020 | 373 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2017 | 268 | 0.030 |
Why?
| | Diet | 1 | 2025 | 1275 | 0.030 |
Why?
| | Neoplasms, Experimental | 1 | 2018 | 173 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2017 | 164 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2017 | 174 | 0.030 |
Why?
| | Rifampin | 1 | 2017 | 82 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2017 | 246 | 0.030 |
Why?
| | Spheroids, Cellular | 1 | 2017 | 73 | 0.030 |
Why?
| | Cytoprotection | 1 | 2017 | 55 | 0.030 |
Why?
| | Indoles | 1 | 2020 | 501 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2022 | 768 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2018 | 402 | 0.030 |
Why?
| | Longevity | 1 | 2018 | 173 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1495 | 0.030 |
Why?
| | Mercury | 1 | 2016 | 40 | 0.030 |
Why?
| | Phylogeny | 1 | 2020 | 1019 | 0.030 |
Why?
| | Sulfur | 1 | 2016 | 64 | 0.030 |
Why?
| | Superoxide Dismutase | 1 | 2017 | 301 | 0.030 |
Why?
| | Cell Lineage | 1 | 2017 | 376 | 0.030 |
Why?
| | Spleen | 1 | 2017 | 508 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2008 | 8279 | 0.030 |
Why?
| | Neural Pathways | 1 | 2017 | 311 | 0.030 |
Why?
| | Imino Sugars | 1 | 2014 | 1 | 0.030 |
Why?
| | Alkaloids | 1 | 2014 | 28 | 0.030 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2014 | 85 | 0.030 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2014 | 109 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2014 | 148 | 0.030 |
Why?
| | Optical Devices | 1 | 2014 | 13 | 0.030 |
Why?
| | Siloxanes | 1 | 2014 | 7 | 0.030 |
Why?
| | Tin Compounds | 1 | 2014 | 17 | 0.030 |
Why?
| | Semiconductors | 1 | 2014 | 38 | 0.030 |
Why?
| | Bacterial Proteins | 1 | 2020 | 962 | 0.030 |
Why?
| | Precision Medicine | 1 | 2018 | 458 | 0.030 |
Why?
| | Nerve Net | 1 | 2017 | 285 | 0.030 |
Why?
| | Drug Design | 1 | 2014 | 173 | 0.020 |
Why?
| | Exercise | 1 | 2025 | 2201 | 0.020 |
Why?
| | Triazoles | 1 | 2014 | 184 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 583 | 0.020 |
Why?
| | Fibroblasts | 1 | 2017 | 1034 | 0.020 |
Why?
| | DNA Gyrase | 1 | 2011 | 12 | 0.020 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2012 | 97 | 0.020 |
Why?
| | Crops, Agricultural | 1 | 2011 | 31 | 0.020 |
Why?
| | Edible Grain | 1 | 2011 | 49 | 0.020 |
Why?
| | Breeding | 1 | 2011 | 63 | 0.020 |
Why?
| | Hydrolysis | 1 | 2011 | 199 | 0.020 |
Why?
| | Ribosomal Proteins | 1 | 2011 | 91 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1129 | 0.020 |
Why?
| | Heat-Shock Proteins | 1 | 2011 | 138 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1087 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2011 | 510 | 0.020 |
Why?
| | Drug Resistance, Bacterial | 1 | 2011 | 199 | 0.020 |
Why?
| | Tubulin | 1 | 2011 | 147 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2017 | 2050 | 0.020 |
Why?
| | Laminectomy | 1 | 2009 | 31 | 0.020 |
Why?
| | Paraplegia | 1 | 2009 | 61 | 0.020 |
Why?
| | Glycolysis | 1 | 2011 | 340 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2009 | 41 | 0.020 |
Why?
| | Loss of Heterozygosity | 1 | 2009 | 52 | 0.020 |
Why?
| | Transcription Factors | 1 | 2017 | 1742 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2011 | 598 | 0.020 |
Why?
| | Down-Regulation | 1 | 2011 | 627 | 0.020 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2011 | 339 | 0.020 |
Why?
| | Carcinogens | 1 | 2009 | 123 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1331 | 0.020 |
Why?
| | Cell Cycle | 1 | 2011 | 597 | 0.020 |
Why?
| | Genome, Human | 1 | 2009 | 422 | 0.020 |
Why?
| | Disease Progression | 1 | 2013 | 2852 | 0.010 |
Why?
| | Agglutination Tests | 1 | 2005 | 4 | 0.010 |
Why?
| | Blood | 1 | 2005 | 109 | 0.010 |
Why?
| | Glucose Oxidase | 1 | 2003 | 25 | 0.010 |
Why?
| | Silicon | 1 | 2003 | 22 | 0.010 |
Why?
| | Enzymes, Immobilized | 1 | 2003 | 30 | 0.010 |
Why?
| | Child, Preschool | 2 | 2009 | 11799 | 0.010 |
Why?
| | Gold | 1 | 2003 | 116 | 0.010 |
Why?
| | Surface Properties | 1 | 2003 | 410 | 0.010 |
Why?
| | Equipment Design | 1 | 2003 | 530 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2003 | 494 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1990 | 0.010 |
Why?
| | Infant | 1 | 2005 | 10039 | 0.000 |
Why?
|
|
Singh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|